Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
400
¥ millionWording
Conditional
How definitive the wording is.Revised forecast
Fiscal year ended March 2025 · Cumulative second quarterPrevious forecast published 10 May 2024Net Sales27,500→27,500million
0.0%
Operating profit1,400→1,800million
+28.6%
Ordinary income1,600→2,000million
+25.0%
Profit attributable to owners of the parent1,100→1,500million
+36.4%
Net income per share47.79→65.17
+36.4%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
原燃料価格の高止まりが続くなか、化粧品向け機能性微粒子製品の販売が好調であったことに加え、導電性高分子薬剤の販売が伸長したため。
Previous-period results2024年３月期第２四半期実績：売上高27,098百万円、営業利益1,402百万円、経常利益1,655百万円、親会社株主に帰属する四半期純利益1,127百万円、１株当たり四半期純利益48.65円
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥27,500 million → ¥27,500 million（0.0%） |
| Operating profit | ¥1,400 million → ¥1,800 million（+28.6%） |
| Ordinary income | ¥1,600 million → ¥2,000 million（+25.0%） |
| Profit attributable to owners of the parent | ¥1,100 million → ¥1,500 million（+36.4%） |
| Net income per share | ¥47.79 → ¥65.17 |
| Fiscal Period Covered | Fiscal year ended March 2025 |
| Period Covered | Cumulative second quarter |
| Publication date of previous forecast | 10 May 2024 |
| Previous-period results | 2024年３月期第２四半期実績：売上高27,098百万円、営業利益1,402百万円、経常利益1,655百万円、親会社株主に帰属する四半期純利益1,127百万円、１株当たり四半期純利益48.65円 |
| Reason for the revision | 原燃料価格の高止まりが続くなか、化粧品向け機能性微粒子製品の販売が好調であったことに加え、導電性高分子薬剤の販売が伸長したため。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.原燃料価格の高止まりが続くなか、化粧品向け機能性微粒子製品の販売が好調で、導電性高分子薬剤の販売も伸長したため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.